Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling of human Ewing sarcoma (A673) cells treated with cytarabine, doxorubicin and puromycin oral tongue squamous cell carcinomas to identify novel potential prognosticators


ABSTRACT: An increasing number of cancer-associated mutations have been identified. Unfortunately, little therapy today exploits these tumor-specific genetic lesions. Often, the resulting oncoproteins have been intractable to easy manipulation with current small molecule screening approaches. To overcome this impasse, we developed an expression-based approach to small molecule library screening. We applied this platform to the discovery of modulators of the activity of EWS/FLI, the Ewing sarcoma associated oncoprotein. Cytarabine (ARA-C) was identified as the top hit in a small molecule library screen. ARA-C modulates EWS/FLI by decreasing EWS/FLI protein level and has striking effects on cellular viability and transformation in in vitro and in vivo models of Ewing sarcoma. With poor outcomes for patients with relapsed Ewing sarcoma and the well established safety profile of ARA-C, clinical trials testing ARA-C in Ewing sarcoma are warranted. Expression data was created for A673 cells treated with ARA-C and two other compounds used to treat Ewing sarcoma (Puromycin and Doxorubicin) at two doses (EC50 and 2xEC50) and three time points (24 hours, 3 days, and 5 days). Experiment Overall Design: A673 cells were treated with ARA-C (at doses of EC50 and 2xEC50) or vehicle in triplicate and expression profiled at 24 hours, 3 days, and 5 days. To exclude the possibility that ARA-C's modulation of the EWS/FLI signature was simply a non-specific response to treatment with all cytotoxic agents, we asked whether other compounds known to kill Ewing sarcoma cells (Doxorubicin and Puromycin) would induce the EWS/FLI off genome-wide expression pattern. A673 cells were treated with Doxorubicin and Puromycin (at doses of EC50 and 2xEC50) and expression profiled at 24 hours, 3 days, and 5 days.

ORGANISM(S): Homo sapiens

SUBMITTER: Kimberly Stegmaier 

PROVIDER: E-GEOD-6930 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.

Stegmaier Kimberly K   Wong Jenny S JS   Ross Kenneth N KN   Chow Kwan T KT   Peck David D   Wright Renee D RD   Lessnick Stephen L SL   Kung Andrew L AL   Golub Todd R TR  

PLoS medicine 20070401 4


<h4>Background</h4>The presence of tumor-specific mutations in the cancer genome represents a potential opportunity for pharmacologic intervention to therapeutic benefit. Unfortunately, many classes of oncoproteins (e.g., transcription factors) are not amenable to conventional small-molecule screening. Despite the identification of tumor-specific somatic mutations, most cancer therapy still utilizes nonspecific, cytotoxic drugs. One illustrative example is the treatment of Ewing sarcoma. Althoug  ...[more]

Similar Datasets

2007-03-01 | GSE6930 | GEO
2014-05-01 | E-GEOD-56900 | biostudies-arrayexpress
2021-07-06 | PXD016052 | Pride
2019-05-03 | GSE98786 | GEO
2024-02-01 | GSE249578 | GEO
2014-05-01 | GSE56900 | GEO
2022-08-15 | GSE185131 | GEO
2022-08-15 | GSE185130 | GEO
2022-08-15 | GSE185128 | GEO
2022-08-15 | GSE185127 | GEO